US 10995335
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
granted A61PA61P3/06
Quick answer
US patent 10995335 (RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61P, A61P3/06